Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

The Lure of Rare Disease Drugs

November 19, 2015 11:39 am | by Stephanie Guzowski, Editor | Articles | Comments

While rare diseases were historically passed over by pharmaceutical companies in favor of those with larger patient populations, such as cardiac disease and diabetes, today the story reads differently. Sales of orphan drugs are expected to grow at an annual rate of nearly 11 percent per year to about $176 billion in 2020, compared with 4 percent for drugs treating larger populations. Read more...


A 3-D Printing Revolution

November 19, 2015 11:31 am | by Drug Discovery & Development | Videos | Comments

In this one-minute video series, Drug Discovery & Development is highlighting the latest headlines and trends happening within the industry.


FDA Approves Nasal Spray Opioid Overdose Antidote

November 19, 2015 10:37 am | by Ryan Bushey, Associate Editor | News | Comments

Naloxone has been around for 40 years, but it has primarily been available as an FDA-approved injection. Read more...


AMA Calls for Ban of Drug Advertising, as Part of Affordability Initiative

November 19, 2015 10:36 am | by Seth Augenstein, Digital Reporter | News | Comments

Drug costs have skyrocketed in the last year-plus, causing outrage and fueling debates on both sides of the political aisle. The American Medical Association has taken the unprecedented step of calling for a ban to drug advertising direct to consumers, as part of a plan to bring down drug costs. Read more...


Lilly, Merck Expand Immuno-oncology Collaboration with Phase 3 NSCLC Trial

November 19, 2015 9:57 am | News | Comments

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase 3 study in first-line nonsquamous non-small cell lung cancer (NSCLC). Read more...


Thermo Fisher Signs Development Agreement for NGS-Based Companion Diagnostic

November 19, 2015 9:30 am | News | Comments

Thermo Fisher Scientific, the world leader in serving science, has entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal next-generation sequencing (NGS) oncology test that will serve as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) across multiple drug development programs. Read more...


‘Liquid Biopsy’ Could Offer Early Cancer Diagnoses of the Future

November 19, 2015 8:32 am | by Seth Augenstein, Digital Reporter | News | Comments

Cancer starts its assault quietly, and can go unnoticed until after it’s already conquered the body. Elaborate tests, scans and biopsies mean that constant monitoring of all the organs where it may start is not an option. But “liquid biopsies” could pick up a chemical trail in small blood samples, potentially offering the way to screen for any tumor in the future, according to findings by a team of scientists in Sweden.


Global Task Force Tackles Problem of Untreatable Cancers, Disease Relapse

November 19, 2015 8:00 am | by Saarland University | News | Comments

Many cancer therapies are highly toxic, and even when they appear to work, a significant percentage of patients will experience a relapse after only a few months. Read more...


Swaziland Makes Progress in Quest to Eliminate Malaria

November 19, 2015 7:45 am | by Christopher Torchia, Associated Press | News | Comments

Swaziland could eliminate malaria by the end of 2016 or in early 2017. Read more...


Scientists Reveal Structure of Key Cancer Target Enzyme

November 19, 2015 7:30 am | by University of York | News | Comments

Knowledge of the structure will enable a more rational approach to drug design. Read more...


Study Finds Ebola Vaccine is Safe, Stimulates Strong Immune Responses

November 19, 2015 7:15 am | by University of Maryland School of Medicine | News | Comments

The study, carried out in Mali, West Africa and Baltimore, included the first testing of this vaccine in adult health care workers and other at-risk persons in Africa. Read more...


An Easy Pill to Swallow

November 19, 2015 7:00 am | by UC Santa Barbara | News | Comments

The novel drug delivery technology may also apply to a wide spectrum of other therapies. Read more...


Acquisitions Trending in Dermatological Drugs Market

November 18, 2015 11:13 am | News | Comments

LEO Pharma's acquisition of the global dermatology business of Astellas Pharma for almost $725 million confirms Kalorama Information's projection that the worldwide pharmaceutical sector will only expand through mergers and acquisitions for some time to come. Read more...


HIV Could Be Flushed Out of Hiding by Alcoholism Drug Disulfiram

November 18, 2015 11:03 am | by Seth Augenstein, Digital Reporter | News | Comments

HIV can be beaten back by a growing wealth of effective drugs. But it has proven to be a tough survivor, finding a way to hide in patients’ tissue from the attempts to eradicate it. But a drug typically used to treat alcoholism could be the “game changer” to flush it out, according to a group of international researchers. Read more...


Pharma Industry Veterans Launch Vertice Pharma in Partnership with Warburg Pincus

November 18, 2015 10:57 am | News | Comments

Pharmaceutical industry veterans Don DeGolyer and Andrew Saik today announced that they have launched Vertice Pharma, LLC ("Vertice Pharma" or "the Company") in partnership with Warburg Pincus, a global private equity firm focused on growth investing. Read more..



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.